We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Acurx Pharmaceuticals, Inc. (ACXP - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Acurx Pharmaceuticals, Inc. is one of 892 individual stocks in the Medical sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Acurx Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ACXP's full-year earnings has moved 42.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ACXP has returned about 56.2% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -3.7% on a year-to-date basis. This shows that Acurx Pharmaceuticals, Inc. is outperforming its peers so far this year.
Apyx Medical (APYX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 3.7%.
The consensus estimate for Apyx Medical's current year EPS has increased 17.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Acurx Pharmaceuticals, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 436 individual stocks and currently sits at #145 in the Zacks Industry Rank. Stocks in this group have gained about 5.4% so far this year, so ACXP is performing better this group in terms of year-to-date returns.
In contrast, Apyx Medical falls under the Medical - Products industry. Currently, this industry has 78 stocks and is ranked #156. Since the beginning of the year, the industry has moved -14.1%.
Acurx Pharmaceuticals, Inc. and Apyx Medical could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Acurx Pharmaceuticals, Inc. (ACXP - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Acurx Pharmaceuticals, Inc. is one of 892 individual stocks in the Medical sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Acurx Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ACXP's full-year earnings has moved 42.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ACXP has returned about 56.2% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -3.7% on a year-to-date basis. This shows that Acurx Pharmaceuticals, Inc. is outperforming its peers so far this year.
Apyx Medical (APYX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 3.7%.
The consensus estimate for Apyx Medical's current year EPS has increased 17.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Acurx Pharmaceuticals, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 436 individual stocks and currently sits at #145 in the Zacks Industry Rank. Stocks in this group have gained about 5.4% so far this year, so ACXP is performing better this group in terms of year-to-date returns.
In contrast, Apyx Medical falls under the Medical - Products industry. Currently, this industry has 78 stocks and is ranked #156. Since the beginning of the year, the industry has moved -14.1%.
Acurx Pharmaceuticals, Inc. and Apyx Medical could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.